A pharmacogenetic study of escitalopram in autism spectrum disorders.

ABSTRACT:

Objective

To determine the effect of serotonin transporter polymorphism promoter region (5-HTTPLR) genotypic variation (low, intermediate, and high expression groups) on response to escitalopram treatment of children and adolescents with autism spectrum disorders (ASDs).

Method

The study used a forced titration, open label design, with genotype blind until study completion. Participants were children and adolescents aged 4-17 years of age with a confirmed ASD (autistic disorder, Asperger's disorder, or pervasive developmental disorder, not otherwise specified).

Results

There was an interaction between genotype group and time on the Aberrant Behavior Checklist (ABC) Irritability Subscale (primary outcome variable) (linear maximum marginal likelihood estimation=-4.84, Z

SUBMITTER: Owley T 

PROVIDER: S-EPMC2937270 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature